The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.

Nina H SchultzHoa T T TranStine BjørnsenCarola E HenrikssonPer Morten SandsetPål A Holme

Published in: Research and practice in thrombosis and haemostasis (2017)

In this in vitro study the 80% dose of aPCC (40 IU/kg) reversed the anticoagulant effect of apixaban more effectively than the corresponding dose of rFVIIa and PCC both in WB (CT) and PPP (peak, ETP).

Keyphrases

venous thromboembolism
atrial fibrillation
newly diagnosed
end stage renal disease
ejection fraction
computed tomography
magnetic resonance imaging
image quality
magnetic resonance
patient reported outcomes
cell free
pet ct
patient reported